Dynavax Technologies Corporation - DVAX Forward Price-to-Revenue Multiple

Corporate company logo of Dynavax Pharma (DVAX)

Complex FDA certification and patent protection of components make entry into this niche nearly impossible, supporting the current trend. The projected P/S of Dynavax Technologies (DVAX) clearly demonstrates the market valuation, where 5.50 captures the magnitude of this parameter. Growth is based on the monetization of the HEPLISAV-B vaccine and adjuvant supplies, although a limited product portfolio creates certain risks in the face of new innovations.

DVAX Dynavax: Market Cap to Projected Revenue in the range 07/04/2022 - 02/21/2026

Dynavax Pharma (DVAX) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Price Dynavax Technologies Corp|DVAX - Broker Consensus Forecast
- issuer market value details:
Market Valuation Dynavax Pharma|DVAX - Total Enterprise Value
- business book valuation details:
Net Assets per Single Share Dynavax|DVAX - Accounting Capitalization|Market Capitalization to Book Value Ratio dynavax.com|DVAX - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio Dynavax Technologies|DVAX - Long-Term Debt to Equity|Short-Term Debt to Capital Dynavax Technologies|DVAX - Company Aggregate Debts|Debt to Book Value Dynavax Pharma|DVAX - Company Long-Term Indebtedness|Company Current Liabilities Dynavax|Quick Liquidity Indicator dynavax.com
- business earnings and investment ratios data:
DVAX - Profit After Payment of Taxes|Projected Future Earnings Dynavax Technologies|DVAX - Market Cap to Earnings|Forward P/E Multiple Dynavax Technologies Corporation|DVAX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Dynavax Pharma|DVAX - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Dynavax|DVAX - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months dynavax.com|DVAX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Dynavax Technologies
- sales and revenue indicators:
DVAX - Company Revenue|Company Projected Revenue Dynavax Pharma|DVAX - Price to Sales|Forward P/S Multiple Dynavax Pharma
Fundamental company analysis:Dynavax (DVAX)
Manufactured products of Dynavax Pharma

Dynavax Technologies (DVAX) specializes in the development of critical vaccines, the delivery of which depends on global logistical stability. The forward P/S ratio correlates current market capitalization with expected revenue, reflecting market expectations for future sales. By analyzing the trajectory of the forward P/S, an investor can discern the level of priced-in optimism regarding business growth rates. Geopolitical risks and trial disruptions make this metric a sensitive indicator of price stability.

Competitor analysis for Dynavax Technologies

Forward P/S Multiple ARWR (Arrowhead Pharmaceuticals, Inc.)|MIRM: Market Cap to Projected Revenue|ABUS: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Inventiva Corp|Gyre Therapeutics, Inc. (GYRE) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ASMB|GALT (Galectin Therapeutics, Inc.) - Forward P/S Multiple|Forward P/S Multiple Genfit Corp|Forward Price-to-Revenue Multiple DRRX (DURECT Corporation)|Price-to-Projected Revenue Ratio ALGS (aligos.com)|Forward P/S Multiple BIVI (BioVie)|Forward P/S Multiple Galmed Pharmaceuticals Ltd GLMD|NDRA: Forward Price-to-Revenue Multiple|HEPA (Hepion Pharmaceuticals) - Market Cap to Projected Revenue